Verastem (VSTM) Current Deferred Revenue (2011 - 2023)
Verastem (VSTM) posted quarterly Current Deferred Revenue of $327000.0 for Q4 2023, up 68.56% quarter-over-quarter from $194000.0 in Q1 2018.
Powered by 
Analysis
Verastem (VSTM) Current Deferred Revenue (2011 - 2023) Analysis & Trends
Verastem's Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $327000.0 for Q4 2023.
- In Q4 2023, Current Deferred Revenue changed N/A year-over-year to $327000.0; the TTM figure through Dec 2023 stood at $327000.0 (changed N/A YoY), while the FY2023 annual figure was $327000.0, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2023 stood at $327000.0, up from $194000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $327000.0 in Q4 2023, with the low at $327000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 327,000.00 |
| Mar 31, 2018 | 194,000.00 |
| Dec 31, 2017 | 190,000.00 |
| Sep 30, 2017 | 186,000.00 |
| Jun 30, 2017 | 81,000.00 |
| Mar 31, 2017 | 179,000.00 |
| Dec 31, 2016 | 527,000.00 |
| Sep 30, 2016 | 171,000.00 |
| Jun 30, 2016 | 167,000.00 |
| Mar 31, 2016 | 164,000.00 |
| Dec 31, 2015 | 160,000.00 |
| Sep 30, 2015 | 156,000.00 |
| Jun 30, 2015 | 152,000.00 |
| Mar 31, 2015 | 148,000.00 |
| Dec 31, 2014 | 144,000.00 |
| Sep 30, 2014 | 137,000.00 |
| Jun 30, 2014 | 72,000.00 |
| Mar 31, 2014 | 28,000.00 |
| Dec 31, 2013 | 38,000.00 |
| Sep 30, 2013 | 43,000.00 |